Phase 2 Study of PIPE-791 in Idiopathic Pulmonary Fibrosis Initiated by Contineum Therapeutics
Contineum Therapeutics has initiated Phase 2 trial to assess PIPE-791 in patients with Idiopathic Pulmonary Fibrosis.
| Drug | MOA / Company | Stage |
|---|---|---|
| PIPE-791 | Contineum Therapeutics | Lead |
Focal Asset
PIPE-791
Company
Contineum Therapeutics
Indication
Pulmonology / Idiopathic Pulmonary Fibrosis
Signal Score
8.2
Signal assessment
Signal strength
high
Confidence level
moderate
Why it matters
The initiation of the Phase 2 trial for PIPE-791 by Contineum Therapeutics is significant as it introduces a potential competitor in the Idiopathic Pulmonary Fibrosis (IPF) treatment landscape. Positive trial outcomes could shift market dynamics and influence competitive positioning for existing therapies.
Recommended action
Humanexa recommends Monitor.
Analysis
Key milestones include interim results and final efficacy data from the Phase 2 trial.
Related companies & assets
Companies
Assets
Sources & Humanexa intelligence
Related signals
Newsletter
Get signals before the market moves
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.